AFT Leaves X Over AI-Generated Images of Minors 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
WALTHAM, Mass., March 29, 2017 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 16th Annual Healthcare Conference on, April 5, 2017 at 09:20 AM EDT at the Westin Grand Central Hotel in New York, NY.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
